Genelux Corp (GNLX): Cash & Equivalents
$5.33M
As of 2025-12-31
$9.18M
As of 2026-06-30
+137.7%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.33M | -37.7% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $8.56M | -9.1% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $9.42M | n/m | 2025-03-28, Balance as of period end |
| 2022-12-31 | $397.0K | n/a | 2024-03-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Genelux Corp (GNLX) | 2025-12-31 | $5.33M | -37.7% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.39M | +26.9% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $3.12M | -26.7% |
| Bioadaptives, Inc. (BDPT) | 2025-12-31 | $215.2K | -17.8% |
| Aditxt, Inc. (ADTX) | 2024-12-31 | $833.0K | +757.9% |
| Talphera, Inc. (TLPH) | 2025-12-31 | $5.89M | -33.5% |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | $3.0K | -99.8% |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | $60.18M | -43.0% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $58.7K | -9.5% |
Compare GNLX, TCRT, PRFX, BDPT side by side · Screen every company in Pharmaceutical Preparations ↗